Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 58.13
- Piotroski Score 2.00
- Grade Outperform
- Symbol (NUVL)
- Company Nuvalent, Inc.
- Price $92.80
- Changes Percentage (1.79%)
- Change $1.63
- Day Low $90.12
- Day High $94.57
- Year High $113.51
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $105.00
- High Stock Price Target $135.00
- Low Stock Price Target $97.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.42
- Trailing P/E Ratio -32.72
- Forward P/E Ratio -32.72
- P/E Growth -32.72
- Net Income $-126,219,000
Income Statement
Quarterly
Annual
Latest News of NUVL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Nuvalent, Inc. (NUVL) Stock Price, News, Quote & History - Yahoo Finance
Nuvalent, a biopharmaceutical company, has initiated a public offering of $350 million of its Class A common stock to support its cancer-focused kinase therapies. The completion of the offering is sub...
By Yahoo! Finance | 2 months ago -
Nuvalent, Inc. (NUVL): Among Hedge Funds' Top Biotech Stock Picks
The article discusses the risks and potential rewards of investing in biotechnology stocks, focusing on Nuvalent, Inc. (NASDAQ:NUVL). It highlights the importance of deep analysis, diversification, an...
By Yahoo! Finance | 2 months ago -
Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock
Nuvalent, Inc. is a biopharmaceutical company focusing on developing targeted cancer therapies. Despite being ranked 4th on the list of worst cancer stocks by short sellers, Nuvalent has strong market...
By Yahoo! Finance | 2 months ago
